Navigation Links
Baxter International Third Quarter 2008 Financial Results Conference Call
Date:9/17/2008

DEERFIELD, Ill., Sept. 17 /PRNewswire-FirstCall/ -- Baxter International (NYSE: BAX), will host a quarterly conference call to discuss its third quarter 2008 financial results on Thursday, October 16, 2008, at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). To access the call, please dial 866- 238-0637 (domestic) or 703-639-1156 (international). Please dial into the call at least ten minutes prior to the start of the call for the operator to connect you.

This call is being webcast by Thomson/CCBN and can be accessed at Baxter's Web site at http://www.baxter.com/. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission.

The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at http://www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (http://www.streetevents.com), a password-protected event management site.

Baxter International Inc. develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide.

Contact Information:

Investor Relations Conta
'/>"/>

SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Baxter Named to Dow Jones Sustainability Index for Tenth Consecutive Year
2. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
3. Baxter Declares Quarterly Dividend
4. Baxter Raises Full-Year 2008 Outlook Following Strong Second-Quarter Financial Results
5. Bioniche Pharma Acquires Baxters ENLON(R) and ENLON-PLUS(R)
6. Baxters Board of Directors Declares Quarterly Dividend
7. Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook
8. Baxters V-Link Luer-Activated Device With VitalShield Protective Coating Now Available For Hospitals
9. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
10. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
11. Baxter and Its Foundation Contribute Nearly $53 Million in 2007 to Address Critical Needs Locally and Globally
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... proprietary technologies are used to discover, develop, manufacture ... bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... as Vice President and Chief Financial Officer. Tom ... information technology operations for Dyadic and will succeed ...
(Date:7/30/2014)... July 30, 2014   Epic Sciences, Inc. ... novel diagnostics to personalize and advance the treatment and ... Gregory T. Lucier as chairman of Epic,s board ... of Life Technologies (formerly Invitrogen). Mr. Lucier joins Epic,s ... its circulating rare cell analysis platform with special focus ...
(Date:7/30/2014)... , July 30, 2014  RXi Pharmaceuticals ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that ... RXI-109, for the reduction of recurrence of ... has been initiated. Logo - ...
(Date:7/30/2014)... July 30, 2014 Connecticut Center for ... based in East Hartford, Conn., was awarded a Rural ... of a project that will determine the feasibility of ... north-central Connecticut. USDA Rural Development provided $53,000 for CCAT ... the second phase of the feasibility study in fiscal ...
Breaking Biology Technology:Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 2Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... 11 Lucid, Inc., (http://www.lucid-tech.com ), a leading ... Colin Stahel as Director, Asia Pacific Region., ... the newly created,position based on his extensive medical ... experience in the development of medical,technology and pre-cancer ...
... Belgium, December 11 , - TB-402 Shows ... Prevention of Thromboembolic Disorders., ThromboGenics NV (Euronext ... disease, announced that the results of the,first Phase ... the prestigious,American Society of Hematology (ASH) 49th Annual ...
... Mass., Dec. 10 Cambridge Research &,Instrumentation, Inc. ... breakthrough system that converts any brightfield or,fluorescent microscope ... of a larger specimens, such as embryos,zebrafish, plants, ... can,be mounted onto a fluorescent macroscope. The Nuance ...
Cached Biology Technology:Lucid Expands Support Internationally: Dr. Colin Stahel appointed Director for Asia Pacific Region 2ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 2ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 3ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting 4CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy 2
(Date:7/30/2014)... Scientists are searching through a massive collection of ... 50 years ago, and the effort is yielding fresh ... inhabited. , When the collection is fully curated, a ... the largest unbiased Dominican amber collection in the world, ... discovery thus far is that of a pygmy locust, ...
(Date:7/30/2014)... Wayne State University,s College of Engineering recently received ... for the project, "Nanoparticle-directed synthesis of organic nanorods." ... nanotechnology is the creation and utilization of functional ... functions. A major bottleneck in scaling up nanotechnology ... different functional materials into one device. A research ...
(Date:7/30/2014)... major interest in neuroscience. A large number of ... of Wallerian degeneration: transcription factor activation, immune response, ... responses in the distal segment of the sciatic ... in gene expression between the proximal and distal ... from Nantong University, China used microarrays to analyze ...
Breaking Biology News(10 mins):Decades-old amber collection offers new views of a lost world 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... 10, 2010) -- Just as the path of photons of ... magnetic moment can be controlled using a magnetic mirror. Research ... the feasibility of using magnetic domain walls to direct and ... "We are looking for ways to build magnetic ...
... , This release is available in Spanish ... were found to have low serum (blood) zinc concentrations during ... and the National Institute of Aging. The scientists ... 50 percent less likely to develop pneumonia than those with ...
... - A new technology enabling tiny machines called ... super-accurate and precise sensors for crime-scene forensics, environmental ... enable researchers to create a "nose-on-a-chip" for tracking ... gaseous substances, as well as a new class ...
Cached Biology News:Adequate zinc eases pneumonia in elderly 2Innovation could bring super-accurate sensors, crime forensics 2Innovation could bring super-accurate sensors, crime forensics 3Innovation could bring super-accurate sensors, crime forensics 4
...
Recalibration of HL-2000-CAL products...
Mature rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and processed within 45 minutes. It is then filtered through gauze, pooled in an ...
Several Pichia pastoris strains are available to allow you to optimize expression and recovery of your protein of interest. Table 1 provides information to help you choose the appropriate strain....
Biology Products: